

AMENDED CLAIMS

Received by the International Bureau on 13 May 2006 (13/05/06)


+


STATEMENT

1. A method for identifying a ligand of NPC1L1 comprising:


contacting human NPC1L1 with a detectably labeled substituted 2-azetidinone glucuronide and a candidate compound; and

determining whether said candidate compound binds to human NPC1L1; wherein binding of said candidate compound to human NPC1L1 modulates binding of said detectably labeled substituted 2-azetidinone glucuronide to human NPC1L1, wherein the detectably labeled substituted 2-azetidinone glucuronide has a binding affinity K_D value for human NPC1L1 that is 200nM or lower, and wherein said modulation indicates that the candidate compound is a ligand that binds to human NPC1L1.
2. The method of claim 1, wherein the K_D value is 100nM or lower.
3. The method of claim 1, wherein the K_D value is 50nM or lower.
4. The method of claim 1, wherein the K_D value is 20nM or lower.
5. The method of claim 1, wherein the K_D value is 10nM or lower.
6. The method of claim 1, wherein the substituted 2-azetidinone-glucuronide is selected from the group consisting of a compound of Formula I and a compound of Formula II.






7. The method of claim 6, wherein the substituted 2-azetidinone-glucuronide comprises a detectable label from the group consisting of ^{35}S and ^{125}I .
8. The method of claim 7, wherein the detectable label is ^{35}S .
9. The method of claim 6, wherein the substituted 2-azetidinone-glucuronide is a compound of Formula II,



wherein R^9 comprises an $-\text{SO}_2-$ group.

10. The method of claim 9, wherein the substituted 2-azetidinone-glucuronide is a compound of Formula II



is labeled with ^{35}S .

11. A method for identifying a ligand of NPC1L1 comprising:
 contacting human NPC1L1 with a detectably labeled substituted 2-azetidinone glucuronide of Formula II and a candidate compound; and
 determining whether said candidate compound binds to human NPC1L1;
 wherein binding of said candidate compound to human NPC1L1 modulates binding of said detectably labeled substituted 2-azetidinone glucuronide of Formula II to human NPC1L1, and wherein said modulation indicates that the candidate compound is a ligand that binds to human NPC1L1.

12. The method of claim 11, wherein R^9 of the detectably labeled substituted 2-azetidinone glucuronide of Formula II comprises an $-\text{SO}_2-$ group.


13. The method of claim 11, wherein the detectably labeled substituted 2-azetidinone glucuronide of Formula II is labeled with ^{35}S .

14. The method of claim 11, wherein the detectably labeled substituted 2-azetidinone glucuronide of Formula II has a binding affinity K_D value for human NPC1L1 that is 200nM or lower.

15. The method of claim 14, wherein the K_D value is 100nM or lower.

16. The method of claim 14, wherein the K_D value is 50nM or lower.

17. The method of claim 14, wherein the K_D value is 20nM or lower.
18. The method of claim 14, wherein the K_D value is 10nM or lower.
19. The method of claim 1 wherein the detectably labeled substituted 2-azetidinone glucuronide is labeled with ^{35}S .
20. The method of claim 1 wherein the detectably labeled substituted 2-azetidinone glucuronide is ^{35}S -labeled compound 2



2.